Loss Widens to $11.1M as Racura Boosts Clinical Trials and Patents

Scientific Breakthrough Positions Racura at Oncology Frontier

Racura Oncology Ltd (ASX:RAC) has unveiled a leap in understanding of its lead candidate, (E,E)-bisantrene, now recognised as a potent silencer of the MYC gene, an oncogenic driver implicated in over 70% of cancers. This mechanism, involving binding to G-quadruplex DNA structures, offers a tangible path to target MYC, long deemed undruggable by the pharmaceutical industry. The company’s discovery of multiple isomers of bisantrene, with only the (E,E) form active, has fortified its intellectual property position through new composition of matter patents, potentially securing two decades of protection.

These scientific advances have catalysed a strategic pivot, with Racura rebranding from Race Oncology to reflect this new chapter and expanding its clinical focus beyond acute myeloid leukaemia (AML) into EGFR-mutated non-small cell lung cancer (NSCLC) and cardioprotection in solid tumours.

Clinical Programs Progress Amid Funding Strength

The company is advancing three clinical trials for its proprietary RC220 formulation of (E,E)-bisantrene. The Phase 3 EMILI trial targets AML, leveraging the drug’s prior regulatory approval history in France and its MYC-silencing properties. Meanwhile, the Phase 1a/b HARNESS-1 trial is exploring RC220 in combination with osimertinib for EGFR-mutated NSCLC, aiming to overcome resistance to tyrosine kinase inhibitors. The first patient was treated in June 2026 at Monash Health, with no adverse events reported. The CPACS trial investigates RC220’s dual role in enhancing anticancer efficacy and cardioprotection alongside doxorubicin, with dose escalation progressing smoothly across sites in Australia, Hong Kong, and South Korea.

Racura’s clinical ambitions are underpinned by a solid financial foundation, having raised over $34 million during the year through option conversions, private placements, and underwriting arrangements. The company closed FY2026 with $34.3 million in cash and equivalents, providing a runway into calendar year 2028 to deliver key clinical milestones and pursue commercial opportunities. Notably, no dividends were declared, reflecting ongoing investment in R&D and clinical development.

Financial Results Reflect Investment Phase and Operational Expansion

Despite the scientific and clinical momentum, Racura reported a net loss after tax of $11.09 million for FY2026, more than doubling the prior year’s $4.79 million loss. Revenues fell 22.2% to $613,291, primarily reflecting the clinical-stage nature of the business and limited commercial sales. Operating expenses rose sharply, driven by increased research and development costs, share-based payments, and a non-cash loss on extinguishment of liability related to option-based bonus settlements.

The balance sheet shows a healthy increase in issued capital to $101 million, reflecting successful capital raises and option exercises. Net tangible assets per share improved to 17.44 cents from 7.76 cents, signalling strengthened shareholder equity despite accumulated losses nearing $73.3 million.

Leadership and Governance Focus on Execution and Value Creation

Racura’s board and executive team, led by Executive Chair Peter Smith and CEO Daniel Tillett, are steering the company through this critical development phase. Both executives hold significant share and option interests, aligning management incentives with shareholder value creation. The remuneration report highlights a mix of fixed and performance-based compensation, with recent option grants tied to clinical and corporate milestones.

Collaborations with leading institutions such as Emory University, Purdue University, and Monash Health bolster Racura’s scientific and clinical capabilities. The company is actively exploring partnerships and licensing deals to accelerate global access to RC220.

What Lies Ahead for Racura Oncology

Looking forward, Racura aims to initiate the pivotal AML Phase 3 trial and continue patient recruitment and dose escalation in its lung cancer and cardioprotection studies. The company’s strong cash position supports these ambitions, but the path to commercialisation remains contingent on clinical outcomes and regulatory approvals. Investors will be watching closely for initial efficacy signals from HARNESS-1 and progress in the EMILI trial, as well as patent grant developments that could solidify Racura’s competitive moat.

While the financial results underscore the high costs and risks inherent in biotech development, Racura’s breakthroughs on the MYC gene front and its multi-pronged clinical approach position it as a noteworthy player in the oncology sector. The next 12 to 18 months will be pivotal in translating scientific promise into tangible shareholder value.